These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 29196440)
1. Report on the Third FDA-AACR Oncology Dose-Finding Workshop. Emens LA; Bruno R; Rubin EH; Jaffee EM; McKee AE Cancer Immunol Res; 2017 Dec; 5(12):1058-1061. PubMed ID: 29196440 [TBL] [Abstract][Full Text] [Related]
2. Report on the FDA-AACR Immuno-oncology Drug Development Workshop. Curran C; Sharon E Cancer Immunol Res; 2017 Apr; 5(4):282-285. PubMed ID: 28373216 [TBL] [Abstract][Full Text] [Related]
4. Highlights in kidney cancer from the 2016 American Society of Clinical Oncology Annual Meeting. Clin Adv Hematol Oncol; 2016 Aug; 14(8):594-6. PubMed ID: 27487102 [No Abstract] [Full Text] [Related]
6. Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life Cycle. Jänne PA; Kim G; Shaw AT; Sridhara R; Pazdur R; McKee AE Clin Cancer Res; 2016 Jun; 22(11):2613-7. PubMed ID: 27250931 [TBL] [Abstract][Full Text] [Related]
7. Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop. Bast RC; Thigpen JT; Arbuck SG; Basen-Engquist K; Burke LB; Freedman R; Horning SJ; Ozols R; Rustin GJ; Spriggs D; Wenzel LB; Pazdur R Gynecol Oncol; 2007 Nov; 107(2):173-6. PubMed ID: 17950384 [TBL] [Abstract][Full Text] [Related]
8. AACR meeting highlights new findings on drug resistance, targeted therapies. Printz C Cancer; 2013 Sep; 119(18):3259. PubMed ID: 24037707 [No Abstract] [Full Text] [Related]
9. Cancer therapy: an evolved approach. Willyard C Nature; 2016 Apr; 532(7598):166-8. PubMed ID: 27075079 [No Abstract] [Full Text] [Related]
10. Targeted agents: the rules of combination. Kwak EL; Clark JW; Chabner B Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5232-7. PubMed ID: 17875749 [TBL] [Abstract][Full Text] [Related]
11. Lessons Learned: Dose Selection of Small Molecule-Targeted Oncology Drugs. Bullock JM; Rahman A; Liu Q Clin Cancer Res; 2016 Jun; 22(11):2630-8. PubMed ID: 27250934 [TBL] [Abstract][Full Text] [Related]
12. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736 [TBL] [Abstract][Full Text] [Related]
13. At the crossroads of cancer stem cells and targeted therapy resistance. Wang A; Qu L; Wang L Cancer Lett; 2017 Jan; 385():87-96. PubMed ID: 27816488 [TBL] [Abstract][Full Text] [Related]
14. New directions in cancer research 2003: technological advances in biology, drug resistance, and molecular pharmacology. Franks ME; Macpherson GR; Lepper ER; Figg WD; Sparreboom A Drug Resist Updat; 2003 Dec; 6(6):301-12. PubMed ID: 14744494 [TBL] [Abstract][Full Text] [Related]
15. Personalized medicine in oncology: a personal view with myths and facts. Beijnen JH; Schellens JH Curr Clin Pharmacol; 2010 Aug; 5(3):141-7. PubMed ID: 20406176 [TBL] [Abstract][Full Text] [Related]
16. Dose-response relationship in experimental and clinical oncology. Brade WP; Freireich EJ; Goldin A Cancer Treat Rev; 1984 Dec; 11(4):279-83. PubMed ID: 6398757 [No Abstract] [Full Text] [Related]
18. High-Throughput Testing of Novel-Novel Combination Therapies for Cancer: An Idea Whose Time Has Come. Scarlett UK; Chang DC; Murtagh TJ; Flaherty KT Cancer Discov; 2016 Sep; 6(9):956-62. PubMed ID: 27587468 [TBL] [Abstract][Full Text] [Related]